Certolizumab Pegol Effectiveness and Retention Rate in Psoriatic Arthritis. Real Life Data

被引：0
|
作者：
Conesa, Arantxa [1 ]
Fernandez, Manuel [2 ]
Exposito, Rosa [3 ]
Campos, Jose [4 ]
Ramon Lamua, Jose [5 ]
del Pilar Navarro, Maria [6 ]
Rubio-Munoz, Paula [7 ]
Ahijado-Guzman, Pilar [8 ]
Gonzalez, Carlos M. [9 ]
机构：
[1] Hosp Clin Univ Valencia, Valencia, Spain
[2] Hosp Univ Guadalajara, Guadalajara, Spain
[3] Hosp Comarcal Laredo, Rheumatol, Laredo, Spain
[4] Hosp Univ Puerta de Hierro Majadahonda, Rheumatol, Madrid, Spain
[5] Hosp Henares, Madrid, Spain
[6] Hosp Fuenlabrada, Fuenlabrada, Spain
[7] Hosp Univ Germans & Trias Pujol, Rheumatol, Badalona, Spain
[8] Fuenlabradas Hosp, Rheumatol Unit, Madrid, Madrid, Spain
[9] Hosp Gen Univ Gregorio Maranon, Rheumatol, Madrid, Spain
来源：
ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1518
引用
收藏
页数：3
相关论文
共 50 条
  • [21] DISEASE DURATION AND HLA-B27 POSITIVITY ALTER LONGTERM RETENTION RATE OF CERTOLIZUMAB PEGOL IN PATIENTS WITH PSORIATIC ARTHRITIS
    Koca, S. S.
    Pehlivan, Y.
    Akar, S.
    Senel, S.
    Karadeniz, H.
    Sosyal, O.
    Yazici, A.
    Yilmaz, S.
    Sagir, R. Piskin
    Inanc, N.
    Karatas, A.
    Cetin, G. Yildirim
    Onen, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1317 - 1317
  • [22] Clinical efficacy and safety of certolizumab pegol in cutaneous symptoms on psoriasis in patients with psoriatic arthritis: A retrospective analysis in real life
    Dattola, Annunziata
    Mazzeo, Mauro
    Di Stefano, Flavia
    Manfreda, Valeria
    Vollono, Laura
    Di Raimondo, Cosimo
    Di Matteo, Eleonora
    Bianchi, Luca
    DERMATOLOGIC THERAPY, 2020, 33 (03)
  • [23] Renal sarcoidosis associated with certolizumab pegol treatment for psoriatic arthritis
    Hum, Ryan M.
    Kanigicherla, Durga A.
    Ho, Pauline
    OXFORD MEDICAL CASE REPORTS, 2022, 2022 (12): : 414 - 416
  • [24] Hypersensitivity reaction to certolizumab pegol in a patient affected by psoriatic arthritis
    Napolitano, Maddalena
    Gallo, Lucia
    Megna, Matteo
    Fabbrocini, Gabriella
    Nocerino, Mariateresa
    Abategiovanni, Luisa
    Patruno, Cataldo
    DERMATOLOGIC THERAPY, 2019, 32 (03)
  • [25] COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS, AXIAL SPONDYLOARTHRITIS, AND PSORIATIC ARTHRITIS IN ROMANIA
    Codreanu, C.
    Mogosanu, C.
    Joita, M.
    Purcaru, O.
    VALUE IN HEALTH, 2014, 17 (07) : A379 - A379
  • [26] CERTOLIZUMAB PEGOL IN A SPANISH COHORT OF PATIENTS WITH PSORIATIC ARTHRITIS - PRELIMINARY RESULTS
    Reina, D.
    Mateo, L.
    Prior, A.
    Laiz, A.
    Moreno, M.
    Juanola, X.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (04) : 722 - 722
  • [27] LONGTERM RETENTION RATE OF CERTOLIZUMAB PEGOL IN AXIAL SPONDYLOARTHRITIS IS HIGHER: DATA FROM TURKBIO
    Koca, S. S.
    Pehlivan, Y.
    Akar, S.
    Senel, S.
    Guler, A. Avanoglu
    Sosyal, O.
    Yazici, A.
    Yilmaz, S.
    Sagir, R. Piskin
    Inanc, N.
    Karatas, A.
    Cetin, G. Yildirim
    Atagunduz, P.
    Onen, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1266 - 1267
  • [28] Health-related quality of life in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis treated with certolizumab pegol
    Sarobe, Maite
    Arrondo, Amaya
    Ibarrondo, Oliver
    Mar, Javier
    FARMACIA HOSPITALARIA, 2022, 46 (01) : 27 - 30
  • [29] BUDGET IMPACT ANALYSIS OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS IN GREECE
    Tzanetakos, C.
    Vassilopoulos, D.
    Kourlaba, G.
    Christou, P.
    Maniadakis, N.
    VALUE IN HEALTH, 2015, 18 (07) : A638 - A639
  • [30] Certolizumab Pegol: A Review of Its Use in Patients with Axial Spondyloarthritis or Psoriatic Arthritis
    Sohita Dhillon
    Drugs, 2014, 74 : 999 - 1016
12345